Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Endostar + Chemo in Unresectable Stage III NSCLC
NCT06617936Phase 2Recruiting
- Start
- Aug 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab and endostar in non-small cell lung cancer (NSCLC) (2 arms). Primary endpoint: Surgical resection rate. Started Aug 2024; status: recruiting.
02
Drugs
tislelizumabendostar
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06617936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06617936.